

Applicants : Virginia M. Litwin, et al.  
U.S. Serial No : Not Yet Known  
Filed : June 25, 2001  
Page 2

applicants' right to pursue the subject matter of these claims in a later-filed application and please add new claims 40-45 as follows:

- Ar*
- 
- 40. (New) A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of a monoclonal antibody or portion thereof effective to (a) specifically inhibit 67% or greater of fusion of a CD4+ PM-1 cell to a HeLa cell expressing envelope glycoprotein from HIV-1<sub>JR-FL</sub>, and (b) inhibit 18% or less of fusion of a CD4+ SUP-T1 cell to a HeLa cell expressing envelope protein from HIV-1<sub>LAI</sub>, wherein the antibody (i) does not crossreact with HIV-1 envelope glycoprotein or CD4, (ii) reacts with an antigen on the surface of a PM-1 cell, and (iii) does not react with an antigen on the surface of a SUP-T1 cell, so as to thereby inhibit HIV-1 infection of the CD4+ cell.--
- 41. (New) The method of claim 40, wherein the monoclonal antibody is a chimeric monoclonal antibody.--
- 42. (New) The method of claim 40, wherein the monoclonal antibody is humanized.--
- 43. (New) The method of claim 40, wherein the monoclonal antibody is a human monoclonal antibody.--
- 44. (New) The method of claim 40, wherein the portion of the monoclonal antibody is a single chain antibody or an antigen binding fragment.--
- 45. (New) The method of claim 40, wherein the monoclonal antibody is labeled with a detectable marker.--

DRAFT DRAFT DRAFT